XU Xiao-jun, XU Yan-jun, CAI Qiu-mao, SONG Xiu-ling, ZHOU Shao-en, MENG Rui-ling, XU Hao-feng,XIA Liang. Quality analysis of death cause reports in medical institutions in Guangdong, 2005-2012[J].S China J Prev Med, 2013, 39(3): 22-27.
[1] 谭建明.移植感染学[M].北京:人民卫生出版社, 2006:249-268. [2] 李洪源,王志玉. 病毒学检验[M].北京:人民卫生出版社, 2006:54-56. [3] LANDRY M L, STANAT S , BIRON K , et al. A Standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates[J]. Antimicrob Agents Chemother ,2000, 44(3): 688-692. [4] GILBERT C, BOIVIN G. Human cytomegalovirus resistance to antiviral drugs[J]. Antimicrob Agents Chemother, 2005, 49(3):873-883. [5] NICHOLS W G, COREY L, GOOLEY T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes[J]. Blood, 2001,97(4):867-874. [6] ERICE A , BORRELL W L, MILLER W J,et al . Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus(CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis[J]. J Infect Dis,1998,178(2):531-534. [7] ECKLE T, LANG L, PRIX G,et al . Rapid development of ganciclovir-resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune cell recovery[J]. Bone Marrow Transplant,2002,30(7):433-439. [8] SPRINGER K L , CHOU S, LI S ,et al. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients[J]. J Clin Microbiol, 2005, 43(1): 208-213. [9] 周琳,钱景,蔡挺,等. 心肺移植患者巨细胞病毒耐更昔络韦基因突变研究[J]. 中华传染病杂志, 2002,20(1):37-40. [10] 王波, 李月琴,田传军,等. 人巨细胞病毒临床低传代病毒株UL97基因的克隆与分析[J]. 暨南大学学报(自然科学版), 2005,26(5): 694-699. [11] 章莉,张明,方风琴,等. 人巨细胞病毒临床分离株对更昔洛韦耐药的表型分析[J]. 检验医学,2009,24(9):646-650. [12] ZHANG Y,ZHAO Z ,SUN J, et al. A new